Oramed Pharmaceuticals Inc. (ORMP) Research
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Market snapshot
- Symbol
- ORMP
- Price
- $3.88
- Day change
- +2.37%
- Market cap
- $158.8M
- P/E ratio
- 1.44x
- 52-week range
- 1.98-5.01
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Peer companies
Recent insider activity
- KIDRON NADAV — F-InKind (44818 shares) on 2026-03-30
- Kidron Miriam — F-InKind (435084 shares) on 2026-03-30
- Kidron Miriam — A-Award (119558 shares) on 2026-03-17
- KIDRON NADAV — A-Award (167005 shares) on 2026-03-17
- Hexter Joshua — A-Award (95889 shares) on 2026-03-17
Open Oramed Pharmaceuticals Inc. (ORMP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.